CD8A and adenocarcinoma: For fifteen patients with adenocarcinoma (75.0%), more distinctive patterns were observed in CD3+ (P = 0.078), CD8+ (P = 0.055), FOXP+ (P = 0.016), and PD1+ (P = 0.016) TILs (Additional file 2: Figure S2).